Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback